Preclinical development of a new drug for cognitive disorders including|Alzheimer¿s disease - Texts

Home
Main Navigation
Content
Search
Help

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

18018.2 PFLS-LS

Project title

Preclinical development of a new drug for cognitive disorders including|Alzheimer¿s disease

Texts for this project

	German	French	Italian	English
Short description		-	-
Abstract		-	-

Inserted texts

Category	Text
Short description (German)	Preclinical development of a new drug for cognitive disorders including Alzheimer¿s disease
Short description (English)	Preclinical development of a new drug for cognitive disorders including\|Alzheimer¿s disease
Abstract (German)	The CTI project 13875.1 PFLS-LS lead to the discovery of compounds HiQ0013 specific for the á7 neuronal nicotinic acetylcholine receptor and HiQ0025 which is specific for the á3â2\|subtype. HiQ0013 a partial agonist at á7 enhances the response to acetylcholine at concentration in the nanomolar range. HiQ0013 was found to be active in rodents and in aged monkeys. The aim of this project is to complete preclinical testing and to consolidate data obtained at backup candidates.
Abstract (English)	The CTI project 13875.1 PFLS-LS lead to the discovery of compounds HiQ0013 specific for the á7 neuronal nicotinic acetylcholine receptor and HiQ0025 which is specific for the á3â2\|subtype. HiQ0013 a partial agonist at á7 enhances the response to acetylcholine at concentration in the nanomolar range. HiQ0013 was found to be active in rodents and in aged monkeys. The aim of this project is to complete preclinical testing and to consolidate data obtained at backup candidates.